Phylonix is developing and marketing novel in vivo zebrafish based eZ-Screens™, for assessing drug induced toxicity and efficacy in disease models for cancers, central nervous system, cardiovascular system, and apoptosis. The company also performs gene knock down and target identification and validation services. Custom studies and screening partnerships are also available.
In contrast to other vertebrate models, zebrafish completes embryogenesis in the first 72 hours. Most of the internal organs, including the cardiovascular system, gut, liver and kidney, develop rapidly in the first 24-48 hours. Zebrafish embryos are completely transparent, facilitating observation and analysis. All the precursor tissues of the brain, eyes, heart and musculature can be easily visualized using light microscopy. An important advantage of this animal model is that the morphological and molecular basis of tissue and organ development is, in general, either identical or similar to other vertebrates, including humans. Since single embryos can be maintained in fluid volumes as small as 100 µl for the first five to six days of development, they can be kept in individual microtiter wells. Reagents can then be added directly to the solution in which the embryos develop, simplifying drug dispensing and facilitating analysis. Zebrafish larva, which are permeable to small molecules, provide easy access for drug administration and vital dye staining. Small molecules, including peptides, dyes and drugs can be simply dissolved in fish water and freely diffuse into the zebrafish in the presence of carrier (e.g. 0.1% DMSO). Additional advantages include: their small size, easy maintenance and breeding, and high productivity. Use of zebrafish as an alternative animal model for drug screening can greatly accelerate the drug screening process, decrease costs, and provide more accurate results than cell-based assays.<<Back to Home Page